Bloomberg – FrontPoint Partners LLC plans to close down its $1.5 billion health-care hedge funds after a portfolio manager allegedly received tips about the results of Human Genome Sciences Inc. trials for the drug Albuferon, according to a person briefed on the firm’s plans.
The firm expects to return capital to clients before the end of this month, said the person, who asked not to be named because the funds are private.
